#药闻简讯#$Mersana Therapeutics(MRSN)$XMT-1660 靶向B7-H4 的ADC最新临床数据: 1) 在103例已知B7-H4肿瘤表达的患者中,约44%的肿瘤比例评分为70%或更高,Mersana初步将其表征为“B7-H4高”。 2)在所有B7-H4高肿瘤中,可评估患者(基线时有可测量疾病且至少有一次基线后扫描的患者)的确诊客观缓解率(ORR)为2...
港安健康国际医疗介绍,在一项针对乳腺癌、子宫内膜癌和卵巢癌患者的一期研究中,研究性抗体-药物结合物(ADC)XMT-1660的剂量已经开始。 港安健康科普:XMT-1660是一种B7-H4导向的DolasynthenADC,具有精确、目标优化的药物-抗体比率(DAR6)和经过临床验证的DolaLock微管抑制剂有效载荷,具有可控的旁观者效应。美国FDA已授...
Abstract OT1-03-01: XMT-1660: A Phase 1b trial of a B7-H4 targeted Antibody Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancersdoi:10.1158/1538-7445.SABCS22-OT1-03-01Background: Breast cancer (BC) is the most commonly diagnosed cancer and one of the leading causes of ...
丨监制:张润平
百年征程波澜壮阔,百年大党风华正茂。英文学院团委“英评党史”系列学习活动,旨在以党史为主脉络,挑选能反映百年党史中的重大事件、重要成就和关键历史场景的主旋律影片,重温中国共产党带领人民群众创造的辉煌历史,展现中华民族的伟大复兴之路,并以撰...
B7-H4 is a poor prognostic factor and is overexpressed in several cancers including endometrial, ovarian, and breast. As a member of the CD28/B7 family of cell surface proteins, it promotes tumorigenesis by suppressing anti-tumor immunity XMT-1660 is a B7-H4-targeted Dolasynthen ADC with a ...
猴痘疫情在非洲大陆持续蔓延,并已蔓延至贝宁、喀麦隆、中非共和国、刚果、刚果民主共和国、加纳、利比里亚、莫桑比克、尼日利亚、南非、肯尼亚、布隆迪等非洲国家。根据非洲疾病预防控制中心8月9日数据,今年以来,非洲有13个国家报告了17541例猴痘病例,死亡517例,其中仅刚果(金)就报告...
XMT-1660 is comprised of an anti-B7-H4 antibody site-specifically conjugated to Dolasynthen, with a total of 6 DolaLock Auristatin F-HPA (AF-HPA) anti-tubulin payloads per antibody (DAR-6).To select the optimal ADC, three ADCs using the same antibody and DolaLock payload were compared:...
The XMT-1660 ADC contains 6 DolaLock Auristatin F-hydroxypropyl amide (AF-HPA) anti-tubulin payloads per antibody (DAR-6). Previously, we demonstrated the cytotoxic effect of XMT-1660 in cell line xenograft and patient derived xenograft models of breast cancer known to have B7-H4 target ...